Inhibitory Effect of Nucleos(t)ide Analogs on Telomerase Activity and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B

Yao-Chun Hsu^{1

2}, Mindie H Nguyen³

Affiliations

¹ Center for Liver Diseases, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
² Division of Gastroenterology, Fu-Jen Catholic University Hospital, New Taipei, Taiwan.
³ Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA.

Comment

Yao-Chun Hsu et al. Am J Gastroenterol. 2020 Feb.

. 2020 Feb;115(2):302-303.

doi: 10.14309/ajg.0000000000000507.

Yao-Chun Hsu^{1

2}, Mindie H Nguyen³

¹ Center for Liver Diseases, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
² Division of Gastroenterology, Fu-Jen Catholic University Hospital, New Taipei, Taiwan.
³ Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA.

No abstract available

Comment on

Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B.
Hsu YC, Wong GL, Chen CH, Peng CY, Yeh ML, Cheung KS, Toyoda H, Huang CF, Trinh H, Xie Q, Enomoto M, Liu L, Yasuda S, Tanaka Y, Kozuka R, Tsai PC, Huang YT, Wong C, Huang R, Jang TY, Hoang J, Yang HI, Li J, Lee DH, Takahashi H, Zhang JQ, Ogawa E, Zhao C, Liu C, Furusyo N, Eguchi Y, Wong C, Wu C, Kumada T, Yuen MF, Yu ML, Nguyen MH. Hsu YC, et al. Am J Gastroenterol. 2020 Feb;115(2):271-280. doi: 10.14309/ajg.0000000000000428. Am J Gastroenterol. 2020. PMID: 31634265
Tenofovir for the Prevention of HCC in Patients With Cirrhosis.
Arslan F, Vahaboglu H. Arslan F, et al. Am J Gastroenterol. 2020 Feb;115(2):302. doi: 10.14309/ajg.0000000000000477. Am J Gastroenterol. 2020. PMID: 31850932 No abstract available.

1. Hsu YC, Wong GL, Chen CH, et al. Tenofovir versus entecavir for hepatocellular carcinoma prevention in an international consortium of chronic hepatitis B. Am J Gastroenterol 2019;115:271–80.
1. Yang HI, Yeh ML, Wong GL, et al. REAL-B Real-world effectiveness from the asia pacific rim liver consortium for HBV risk score for the prediction of hepatocellular carcinoma in chronic hepatitis B patients treated with oral antiviral therapy. J Infect Dis 2019. [Epub ahead of print September 24, 2019.]
1. Hsu YC, Yip TC, Ho HJ, et al. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. J Hepatol 2018;69:278–85.
1. Hsu YC, Ho HJ, Lee TY, et al. Temporal trend and risk determinants of hepatocellular carcinoma in chronic hepatitis B patients on entecavir or tenofovir. J Viral Hepat 2018;25:543–51.
1. Nault JC, Ningarhari M, Rebouissou S, et al. The role of telomeres and telomerase in cirrhosis and liver cancer. Nat Rev Gastroenterol Hepatol 2019;16:544–58.